Inflexion invests in Global Data’s Healthcare division

Inflexion is pleased to announce that it has agreed to partner with GlobalData Plc (“GlobalData”) to carve out its Healthcare division as a standalone entity in a transaction valuing the business at £1.1 billion. The investment is being made by Inflexion’s dedicated minority equity strategy, Partnership Capital.The healthcare data business is the largest division of AIM-listed GlobalData, headquartered in the UK and employing over 1,000 people across 10 countries. Its subscription service offers a one-stop data solution for over 2,000 global customers across large global pharma, pharma & biotech, pharma suppliers, professional services and medical devices manufacturers.

This innovative transaction allows GlobalData to retain a majority stake in the business. GlobalData and Inflexion will work together to accelerate organic growth primarily through securing new clients globally and further cross-selling to existing clients, continuing to invest in the product and content, as well as pursuing selective M&A.

Inflexion’s Partnership Capital Fund has a strong track record in leading corporate partnerships and carve-outs including the recently announced carve-out of aosphere with global law firm Allen & Overy. Others have included partnering with Informa PLC to create Curinos, a global financial data provider, and partnering with the Daisy Group to create Giacom, a platform software business created in 2021.

David Whileman, Head of Partnership Capital, Inflexion: “GlobalData is renowned for creating data and analytical insight for its clients across many verticals. We are really excited about our partnership with them to carve out and expand an independent Healthcare business. This is a tried and tested strategy we’ve successfully pursued many times and another example of Inflexion being the leading minority investment partner.”

Mike Danson, CEO, GlobalData: “This is a significant milestone in GlobalData’s evolution and we are delighted to welcome Inflexion as a shareholder in our Healthcare division. This investment highlights the significant value in our unique data platform and gives us the flexibility to launch a more ambitious approach to growth investment across our portfolio. We believe that we can create substantial value for all shareholders and accelerate GlobalData’s profitable growth over the coming years.”